Although expansion in the presence of high-dose interleukin-2 (IL-2) results in TIL-ACT products in which tumor-specific clonotypes exhibit attenuated epigenetic or phenotypic features of exhaustion, the transferred TILs can readily reacquire features of exhaustion in vivo post ACT.10 The gene discussed is IL2; the disease is neoplasm.